TBPH (STOCKS)
Theravance Biopharma, Inc.
$16.920000
+0.000000 (+0.00%)
Prev close: $16.920000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Rick E. Winningham
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $881.07M
- Employees
- 97
- P/E (TTM)
- 16.76
- P/B (TTM)
- 3.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
5
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.03 | $-0.15 | +0.1162 | +79.48% |
|
Dec 2025 (Q4)
|
$0.21 | $1.24 | -1.0338 | -83.12% |
|
Sep 2025 (Q3)
|
$0.07 | $-0.13 | +0.2009 | +153.48% |
|
Jun 2025 (Q2)
|
$-0.54 | $0.69 | -1.2265 | -178.66% |
Financial Statements
| Revenues | $104.31M |
| Benefits Costs and Expenses | $49.69M |
| Costs And Expenses | $102.02M |
| Operating Expenses | $108.51M |
| Selling, General, and Administrative Expenses | $68.75M |
| Research and Development | $26.01M |
| Operating Income/Loss | -$4.20M |
| Income/Loss From Continuing Operations After Tax | $53.81M |
| Income/Loss From Continuing Operations Before Tax | $31.74M |
| Income Tax Expense/Benefit | $5.11M |
| Net Income/Loss | $53.81M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $53.81M |
| Net Income/Loss Available To Common Stockholders, Basic | $53.81M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.06 |
| Diluted Earnings Per Share | $1.01 |
| Basic Average Shares | 102,174,000 |
| Diluted Average Shares | 103,913,000 |
| Assets | $469.77M |
| Current Assets | $416.66M |
| Noncurrent Assets | $53.11M |
| Fixed Assets | $5.17M |
| Other Non-current Assets | $47.94M |
| Liabilities | $180.07M |
| Current Liabilities | $30.77M |
| Accounts Payable | $652.00K |
| Wages | $7.83M |
| Other Current Liabilities | $22.29M |
| Noncurrent Liabilities | $149.30M |
| Equity | $289.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $289.71M |
| Liabilities And Equity | $469.77M |
| Net Cash Flow From Operating Activities | $53.74M |
| Net Cash Flow From Operating Activities, Continuing | $53.74M |
| Net Cash Flow From Investing Activities | -$107.47M |
| Net Cash Flow From Investing Activities, Continuing | -$107.47M |
| Net Cash Flow From Financing Activities | -$8.44M |
| Net Cash Flow From Financing Activities, Continuing | -$8.44M |
| Net Cash Flow | -$62.16M |
| Net Cash Flow, Continuing | -$62.16M |
| Comprehensive Income/Loss | $53.67M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $53.71M |
| Other Comprehensive Income/Loss | -$137.00K |